<DOC>
	<DOC>NCT01776424</DOC>
	<brief_summary>The primary purpose of this study is to evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban alone is better than aspirin alone in prevention of heart attacks, stroke or cardiovascular death in patients with coronary or peripheral artery disease.</brief_summary>
	<brief_title>Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Coronary or peripheral artery disease Patients with coronary artery disease must also meet at least one of the following: Age â‰¥65, or Age &lt;65 and documented atherosclerosis or revascularization involving at least 2 vascular beds, or at least 2 additional risk factors Need for dual antiplatelet therapy, other nonaspirin antiplatelet therapy or oral anticoagulant therapy Stroke within 1 month or any history of hemorrhagic or lacunar stroke Severe heart failure with known ejection fraction &lt;30% or New York Heart Association (NYHA) class III or IV symptoms Estimated glomerular filtration rate (eGFR)&lt;15 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Cardiovascular events</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Xarelto</keyword>
	<keyword>anticoagulant</keyword>
	<keyword>blood thinner</keyword>
	<keyword>aspirin</keyword>
	<keyword>ASA</keyword>
	<keyword>CAD</keyword>
	<keyword>coronary disease</keyword>
	<keyword>artery disease</keyword>
	<keyword>coronary artery bypass graft</keyword>
	<keyword>stroke</keyword>
	<keyword>heart attack</keyword>
	<keyword>angina</keyword>
	<keyword>arterial vascular disease</keyword>
	<keyword>transient ischemic attack</keyword>
	<keyword>TIA</keyword>
	<keyword>heart disease</keyword>
</DOC>